$47.71
0.691.47%
At close: -
$47.71
0.000.00%
After Hours: Dec 20, 4:05 PM EDT
Comments
Loading...
Apogee Therapeutics (APGE) Forecast
NewsEarningsApogee Therapeutics (APGE) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestApogee Therapeutics (NASDAQ:APGE) Stock Quotes, Forecast and News Summary
Apogee Therapeutics Stock (NASDAQ: APGE) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Apogee Therapeutics (APGE) stock?
You can purchase shares of Apogee Therapeutics (NASDAQ:APGE) through any online brokerage.
Who are Apogee Therapeutics (APGE) competitors?
Other companies in Apogee Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), MoonLake (NASDAQ:MLTX), Centessa Pharmaceuticals (NASDAQ:CNTA), SpringWorks Therapeutics (NASDAQ:SWTX) and PTC Therapeutics (NASDAQ:PTCT).
What is the forecast, or price target, for Apogee Therapeutics (APGE) stock?
Apogee Therapeutics has a consensus price target of $78.67.
What is the current price for Apogee Therapeutics (APGE)?
The stock price for Apogee Therapeutics (NASDAQ: APGE) is $47.71 last updated December 20, 2024 at 4:05 PM EST.
Does Apogee Therapeutics (APGE) pay a dividend?
There are no upcoming dividends for Apogee Therapeutics.
When is Apogee Therapeutics (NASDAQ:APGE) reporting earnings?
Apogee Therapeutics’s Q4 earnings are confirmed for Tuesday, March 4, 2025.
Is Apogee Therapeutics (APGE) going to split?
There is no upcoming split for Apogee Therapeutics.
What sector and industry does Apogee Therapeutics (APGE) operate in?
Apogee Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.